Today, pharmaceutical giant AstraZeneca announced that the US Food and Drug Administration Arthritis Advisory Committee (FDA AAC) voted 10-4 in favor of recommending approval for lesinurad 200 mg tablets.

This is a new drug designed for the treatment of hyperuricemia in association with gout and to be used in combination with a separate xanthine oxidase inhibitor.

Indeed, the AAC voted in favor of the drug after reviewing safety and efficacy data during the important Phase III combination therapy trials. This represents the largest clinical trial data set for gout patients to be treated with combination urate lowering therapies.

READ MORE HERE

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites